North America Infectious Disease Diagnostics Market Outlook (2025-2035)
The North America Infectious Disease Diagnostics Market is set for robust growth from 2025 to 2035, driven by rapid advancements in molecular technologies, increased disease prevalence, and evolving healthcare infrastructure. The region’s focus on early and accurate disease detection, accelerated by the COVID-19 pandemic aftermath, has intensified the adoption of advanced diagnostic platforms. Strategic collaborations among major diagnostics companies, coupled with government support for infectious disease control, continue to shape the market dynamics. The market is poised to leverage next-generation sequencing and point-of-care diagnostics for infectious disease identification, creating significant opportunities for key stakeholders.
Latest Market Dynamics
Key Drivers
- Rising demand for early and accurate disease detection with increasing incidence of infectious diseases, highlighted by Thermo Fisher Scientific’s expansion of molecular diagnostic product lines in 2024.
- Growing adoption of advanced diagnostic technologies such as PCR and NGS, exemplified by Roche Diagnostics launching new high-throughput PCR systems in North America in early 2024.
Key Trends
- Shift towards point-of-care testing, driven by Abbott Laboratories' ID NOW platform expansion in 2024, making infectious disease testing faster and more accessible.
- Integration of artificial intelligence and data analytics in diagnostics workflows, with Hologic, Inc. partnering with AI startups in June 2024 to enhance laboratory efficiency.
Key Opportunities
- Expansion in home-based diagnostics, spurred by QuidelOrtho’s recent OTC infectious disease test approvals from the FDA in 2024.
- Rising government funding and public health initiatives aimed at pandemic preparedness, with increased investment in rapid diagnostic infrastructure by Canadian Health Authorities in 2024.
Key Challenges
- Stringent regulatory compliance and complexities in the approval process, with BioMérieux encountering regulatory delays for certain panels in mid-2024.
- High cost and resource requirements for implementation of advanced molecular platforms, as experienced by smaller clinics integrating NGS technologies.
Key Restraints
- Limited access and affordability in low-resource or rural areas, impacting market penetration, as seen in parts of rural Mexico in 2024.
- Increasing competition from generic kit manufacturers, exerting pricing pressure on established players such as Siemens Healthineers.
North America Infectious Disease Diagnostics Market Share (%) by Type, 2025
In 2025, the market share across diagnostic types reflects strong adoption of molecular diagnostics and immunodiagnostics, driven by the need for precise and rapid infection identification. Molecular diagnostics dominate due to their high sensitivity and specificity, especially critical for timely intervention in disease outbreaks. Immunodiagnostics continue to hold significant share, fueled by ongoing needs for serological and antigen-based testing. Traditional microbiology approaches maintain relevance for comprehensive culture-based analyses, while point-of-care testing grows through decentralized healthcare trends. The chart below illustrates the proportional market distribution, with molecular diagnostics leading the segment.
North America Infectious Disease Diagnostics Market Share (%) by Application, 2025
Hepatitis and HIV remain the principal applications, collectively capturing the majority of the North American infectious disease diagnostics market in 2025. The continued fight against viral hepatitis and persistent public health focus on HIV/AIDS interventions ensure high testing volumes. Influenza diagnostics also exhibit robust demand, notably due to the resurgence in flu surveillance since the COVID-19 pandemic. Emerging applications such as HPV and tuberculosis are rising steadily as screening guidelines and public awareness intensify. Others include diagnostics for less common but significant infectious diseases. The pie chart presents the breakdown of market share by application.
North America Infectious Disease Diagnostics Market Revenue (USD Million, 2020-2035)
The North America Infectious Disease Diagnostics Market showcases strong revenue growth from 2020 to 2035. In 2020, the market stood at 8,200 Million USD. By 2025, it reached 10,550 Million USD, reflecting substantial investments in molecular and point-of-care testing solutions. The projected trajectory points to 19,350 Million USD by 2035, driven by technological innovation, rising healthcare spending, and heightened awareness for early detection. The chart below highlights this upward movement, signifying a dynamic expansion and strengthening competitiveness across diagnostic segments and end-user markets.
North America Infectious Disease Diagnostics Market YOY (%), 2020-2035
Year-on-year (YOY) growth rates in the North America Infectious Disease Diagnostics Market peaked during the COVID-19 pandemic, with 2020-2021 reaching up to 16%. Subsequent years saw a normalization but sustained momentum, with YOY growth averaging 5.2% between 2022 and 2025, and stabilizing to 3.8% through 2035 as the market matures. Growth is propelled by recurring infectious outbreaks, demand for novel diagnostics technologies, and strategic product launches by leading players. The provided chart demonstrates the market’s shifting growth dynamics across the forecast period.
North America Infectious Disease Diagnostics Market Share (%) by Region, 2025
In 2025, the United States maintains the largest share in the North America infectious disease diagnostics market, driven by a mature healthcare system, robust R&D activity, and early adoption of advanced diagnostics. Canada follows, underpinned by strong government initiatives and increasing focus on public health preparedness. Mexico’s share continues to grow modestly, with gradual improvements in healthcare access and investment in laboratory infrastructure. The visual breakdown below clarifies the market share distribution among the key regions.
North America Infectious Disease Diagnostics Market Share (%) by Key Players, 2025
Leading diagnostics companies dominate the North America infectious disease diagnostics market. Abbott Laboratories leads in 2025, leveraging its extensive portfolio and distribution network, followed closely by Roche Diagnostics, known for innovation in molecular platforms. Thermo Fisher Scientific maintains a strong position, supported by continual expansion into high-growth applications. Other global players like Hologic, BD, and Siemens Healthineers round out the competitive landscape. The following chart reflects the respective 2025 market shares among top industry participants.
North America Infectious Disease Diagnostics Market Buyers Share (%) by End User, 2025
Hospitals represent the primary buyers of infectious disease diagnostics in North America for 2025, owing to their central role in acute care, outbreak management, and integration with advanced laboratory facilities. Diagnostic laboratories follow closely, maintaining high test throughput, while clinics and home care segments experience incremental growth as decentralization gains favor. Research institutes and other buyers play specialized roles amid ongoing trends toward personalized and preventative medicine. The chart demonstrates the representative share for each buyer segment.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 10550 |
| Regions | United States, Canada, Mexico |
| Segments | By Type: Immunodiagnostics, Molecular Diagnostics, Microbiology, Traditional Diagnostic Tests, Point-of-Care Testing, Others; By Application: Hepatitis, HIV, Influenza, Tuberculosis, HPV, Others |
| Players | Abbott Laboratories, bioMérieux, Thermo Fisher Scientific, Becton Dickinson and Company (BD), Danaher Corporation, Quidel Corporation, DiaSorin S.p.A., Roche Diagnostics, Hologic, Inc., Siemens Healthineers, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Qiagen N.V., GenMark Diagnostics, Luminex Corporation |
Key Recent Developments
- June 2024: Roche Diagnostics launched an expanded PCR panel for respiratory pathogens in North America, streamlining multiplex disease detection.
- July 2024: Hologic, Inc. announced a strategic partnership with an AI-driven diagnostics firm to enhance infectious disease testing automation.
- August 2024: Abbott Laboratories expanded its molecular diagnostics manufacturing capabilities with a new facility in the United States.
- September 2024: QuidelOrtho received FDA clearance for a new at-home influenza and COVID-19 dual test for rapid screening.
- October 2024: BioMérieux initiated regulatory submissions for its next-generation multiplex syndromic panels for North American approval.
